Relmada Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Relmada Therapeutics has a total shareholder equity of $47.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $55.7M and $8.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$54.12m |
| Equity | US$47.63m |
| Total liabilities | US$8.10m |
| Total assets | US$55.72m |
Recent financial health updates
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16Financial Position Analysis
Short Term Liabilities: RLMD's short term assets ($55.7M) exceed its short term liabilities ($8.1M).
Long Term Liabilities: RLMD's short term assets ($55.7M) exceed its long term liabilities ($12.6K).
Debt to Equity History and Analysis
Debt Level: RLMD is debt free.
Reducing Debt: RLMD has no debt compared to 5 years ago when its debt to equity ratio was 4.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RLMD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RLMD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 09:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Maxim Jacobs | Edison Investment Research |
| Yatin Suneja | Guggenheim Securities, LLC |